Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2024-12-12 00:00:00 ET · period of report 2024-12-10 · accession 0001415889-24-029162 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-12 | 2024-12-10 | SPRY | Chakma Justin | Chief Business Off | M - OptEx | $0.84 | +50.0K | 186.4K | +37% | +$42.0K |
| D | 2024-12-12 | 2024-12-10 | SPRY | Chakma Justin | Chief Business Off | S - Sale+OE | $13.15 | -50.0K | 136.4K | -27% | -$657.5K |
| D | 2024-12-12 | 2024-12-10 | SPRY | Chakma Justin | Chief Business Off | M - OptEx | $0.00 | -50.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-10 | M | A | 50,000 | $0.84 | 186,380 | D | — | — | |
| 2 | Common | Common Stock | 2024-12-10 | S | D | 50,000 | $13.15 | 136,380 | D | — | — | (F1) The weighted average sale price for the transaction reported was $13.1525, and the range of prices were between $12.95 and $13.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-12-10 | M | D | 50,000 | $0.00 | 0 | D | $0.84 · — to 2029-07-04 | 50,000 Common Stock | (F2) Immediately exercisable. |